Avantor, Inc. (AVTR) Stock Analysis
Recovery setup
Healthcare · Medical Instruments & Supplies
Sell if holding. Engine safety override at $9.99: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Elevated put/call ratio: 5.00; Below-average business quality; Below long-term trend.
Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education/government, and advanced technologies customers through its VWR distribution channel and specialty manufacturing brands (J.T. Baker, Masterflex, NuSil). It serves 300,000+... Read more
Sell if holding. Engine safety override at $9.99: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Elevated put/call ratio: 5.00; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 83. Score 5.1/10, moderate confidence.
Passes 6/9 gates (positive momentum, clean insider activity, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
Recent developments
updated 2026-06-10Recent Developments — Avantor, Inc.
Latest news
- NEWS Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday — benzinga Jun 8, 2026 positive
- NEWS Wolfe Research Assumes Avantor at Underperform, Announces Price Target of $7 — benzinga Jun 2, 2026 negative
- NEWS Braze Posts Mixed Q1 Results, Joins Sidus Space, Everpure And Other Big Stocks Moving Lower In Thursday's Pre-Market Ses — benzinga May 28, 2026 neutral
- NEWS RBC Capital Reinstates Sector Perform on Avantor, Announces $9 Price Target — benzinga May 15, 2026 neutral
- NEWS Citigroup Maintains Neutral on Avantor, Lowers Price Target to $9 — benzinga Apr 30, 2026 negative
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-02-25Item 5.02LOW8-K/A: Simon Dingemans appointed to Audit & Finance Committee effective February 19, 2026, amending prior 8-K announcing his election as director in December 2025.SEC filing →
- 2026-02-25Item 5.02LOW8-K/A: Sanjeev Mehra appointed to Compensation & Human Resources Committee and Audit & Finance Committee effective February 19, 2026, amending prior 8-K announcing his election as director in December 2025.SEC filing →
- 2026-04-01Item 5.02HIGHCFO R. Brent Jones resigned to join a company outside life sciences, with 90 days notice. Steven Eck (SVP and Chief Accounting Officer) designated interim CFO pending permanent search. No permanent successor named.SEC filing →
- 2026-04-23Item 5.02MEDIUMEVP Benoit Gourdier transitioning to new role supporting segment integration, expected to depart by December 31, 2026. Ludovic Brellier appointed EVP Bioscience and Medtech Products and Chief Transformation Officer effective May 1, 2026.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Unprofitable operations — net margin -8.4%. Quality floor flags this regardless of sector context.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $9.99: Quality below floor (3.1 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.1/10. Specifically: Elevated put/call ratio: 5.00; Below-average business quality; Below long-term trend. Chart setup: Death cross but MACD improving, RSI 83. Prior stop was $9.22. Score 5.1/10, moderate confidence.
Take-profit target: $9.85 (-0.6% upside). Prior stop was $9.22. Stop-loss: $9.22.
Target reached (-12.2% upside); Quality below floor (3.1 < 4.0).
Avantor, Inc. trades at a P/E of N/A (forward 11.4). TrendMatrix value score: 7.4/10. Verdict: Sell.
25 analysts cover AVTR with a consensus score of 3.3/5. Average price target: $10.
What does Avantor, Inc. do?Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education/government,...
Avantor is a global provider of mission-critical products and services to biopharma, healthcare, education/government, and advanced technologies customers through its VWR distribution channel and specialty manufacturing brands (J.T. Baker, Masterflex, NuSil). It serves 300,000+ customer locations in approximately 180 countries with approximately 13,500 employees. More than 85% of net sales are recurring in nature; no single customer exceeds 5% of net sales.